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Strongyloides Stercoralis Infection in a Patient  
with AIDS
Abhik Roy, MD, Gregory Young, MD, Geoffrey Koff, MD, and Tasha Kouvatsos, MD
Case
A 46-year-old male with a past medical history significant for 
acquired immune deficiency syndrome (AIDS) presented with 
constant, non-radiating epigastric pain, nausea, non-bloody 
emesis, weakness, and lethargy. He had emigrated from 
Honduras twenty years prior. The patient denied fever, chills, 
recent travel, animal exposures, or sick contacts. His medications 
included efavirenz/emtricitabine/tenofovir, valganciclovir, 
trimethoprim/sulfamethoxazole, fluconazole, and iron. 
Initial physical examination revealed a thin, lethargic male in 
moderate discomfort, who was afebrile, tachycardic, tachypneic, 
and hypotensive. The remainder of the examination showed 
diffuse pulmonary crackles and epigastric tenderness. Labs 
revealed bandemia and anemia. Urinalysis indicated a urinary 
tract infection (UTI) and antibiotics were started. The initial 
assessment was dehydration secondary to vomiting and UTI. 
Given the patient’s persistent hypotension, he was transferred to 
the medical intensive care unit with concern for sepsis. Volume 
resuscitation with normal saline and packed red blood cells was 
initiated. A computed tomography (CT) scan of the abdomen 
showed small bowel obstruction (SBO) and enterocolitis. After 
resuscitation, the patient was hemodynamically stable. 
Shortly thereafter, the patient again developed hypotension and 
hypoxic respiratory failure, ultimately requiring intubation. A 
chest radiograph (CXR) revealed bilateral pulmonary edema, 
with subsequent chest CT demonstrating worsening alveolar 
infiltrates. A new rash was observed on the patient’s abdomen. 
He was started empirically on steroids and pentamidine for 
possible Pneumocystis jiroveci pneumonia. A bronchoscopy 
was performed and demonstrated diffuse alveolar hemorrhage 
of unknown etiology. Microbiology results from bronchoscopy 
revealed Klebsiella pneumoniae and Strongyloides stercoralis. 
Silver stain, acid fast bacilli, and Legionella were negative. 
Steroids were immediately discontinued. Re-examination of 
prior colonic biopsies obtained on previous admission a few 
weeks prior revealed overlooked evidence of Strongyloides 
infection.
After the diagnosis of Strongyloides hyperinfection, the patient 
was started on oral ivermectin. Rectal ivermectin was started 
one day later secondary to SBO. Both routes of administration 
were continued for fourteen days. The patient’s respiratory 
status gradually improved, but tracheostomy was required 
for prolonged intubation. His SBO resolved and tube feeds 
were started. He was transferred to a general medicine floor. 
Repeat CT of the chest showed marked improvement of diffuse 
alveolar infiltrates, and abdominal CT demonstrated resolving 
enterocolitis. CXR eight days after completing ivermectin was 
normal. The patient did eventually expire from overwhelming 
underlying illness
Strongyloidiasis – Epidemiology and Diagnosis
Strongyloides stercoralis is an intestinal nematode parasite that 
is most commonly found in tropical and subtropical regions 
world wide, with 30-100 million people infected around the 
globe.1 As our case illustrates, many cases in the United States 
are diagnosed in individuals who have previously been in other 
endemic areas of the world.2-3 
Infection with S. stercoralis begins when infectious larval forms 
contact with human skin. Since S. stercoralis is most commonly 
found in the soil and other infected fecal material, walking 
barefoot in endemic areas is considered a significant risk factor. 
The larvae penetrate the skin, enter the blood stream, travel 
hematogenously to the lungs, and are ultimately swallowed into 
the gastrointestinal tract where they mature into adult worms 
and reproduce. Larvae can be passed in feces or re-enter the 
blood stream to cause infection.3
Given this unique life-cycle, the diagnosis of S. stercoralis 
infection is made by detecting larvae in stool or other bodily 
fluids – including sputum and bronchoalveolar lavage fluid. 2-3
Clinical Manifestations
The clinical manifestations of S. stercoralis vary depending on 
the stage of the infection and the host’s immune response. Up to 
50% of infected patients, particularly those with intact immune 
systems, remain asymptomatic.4
During the acute phase of infection (3-4 weeks after infestation), 
most symptomatic patients present with cutaneous, gastroin-
testinal, and pulmonary complaints – all of which were seen in 
our patient. At the site of larval penetration, localized reactions 
occur – inflammation, pruritis, petechiae, and urticarial tracts.4,5 
As the larvae migrate through the lungs, pulmonary symptoms 
such as dry cough, wheezing, and dyspnea occur. Finally, as the 
larvae settle in the gastrointestinal tract, patients experience 
diarrhea and abdominal pain.6
Chronic strongyloidiasis results from the parasite’s ability 
to perpetuate the infectious cycle through the process of 
autoinfection. In symptomatic patients, chronic strongyloi-
diasis affects the same organ systems as in the acute phase, with 
symptoms waxing and waning over years. Chronic infection 
also produces the pathognomonic cutaneous finding of strongy-
loidiasis: larva currens – a transient, urticarial serpiginous 
eruption involving the buttocks, thighs, and lower extremities.3,4
1
Roy, MD et al.: Strongyloides Stercoralis Infection in a Patient with AIDS
Published by Jefferson Digital Commons, 2012
22
Hyperinfection Syndrome and Disseminated 
Strongyloidiasis
In hosts with fully functional immune systems, the rate of S. 
stercoralis autoinfection is controlled over time, and the overall 
parasitic burden remains low. Contrarily, immunocompromised 
hosts lack the balance between excretion and maturation of 
larvae within the gastrointestinal tract leading to higher rates of 
autoinfection and total worm burden, which results in hyperin-
fection syndrome.3,4
During hyperinfection, increased parasite burden leads to the 
exacerbation of gastrointestinal and pulmonary symptoms. 
Reported complications of hyperinfection include intestinal 
obstruction (as seen in our patient), paralytic ileus, intestinal 
bleeding, hemoptysis, diffuse pulmonary hemorrhages, lung 
abscesses, and respiratory compromise (also seen in our 
patient).4,7 Invasion of organs such as the liver, heart, and kidney 
have also been reported – the so called “disseminated strongyloi-
diasis”.3,4 Secondary infections are also common with hyperin-
fection as a result of the compromised intestinal barrier. Patients 
with hyperinfection often have gram negative bacteremia, and 
persistent bacteremia may lead to systemic complications 
including meningitis, peritonitis, and endocarditis.3
Treatment and Prognosis
All patients diagnosed with strongyloidiasis require treatment. 
The drug of choice for the treatment of uncomplicated strongy-
loidiasis is ivermectin – given as 200 ug/kg once daily for 1-2 
days and then repeated in 2-3 weeks to ensure eradication. 
Second line treatment is albendazole.8
For patients with hyperinfection or disseminated disease, oral 
ivermectin remains the treatment of choice with daily adminis-
tration until clinical symptoms resolve and stool tests are 
persistently negative.8
As demonstrated in our patient, those with hyperinfection may 
not tolerate oral therapy, either because of severe infection or 
poor bioavailability of oral medications secondary to gastro-
intestinal complications. In such cases, alternative salvage 
therapies are often required including rectal and subcutaneous 
administration of medications.8 In our case, rectal ivermectin 
was used secondary to small bowel obstruction.
The prognosis for patients with strongyloidiasis depends on the 
severity of infection. Cure rates in patients with uncomplicated 
strongyloidiasis have been reported to be as high as 97%. 
Mortality is significantly higher, however, in patients who 
develop hyperinfection and disseminated strongyloidiasis –
nearly 77 to 87%.9 
Summary
As this case illustrates, strongyloidiasis should be suspected in 
patients with the appropriate constellation of cutaneous, gastro-
intestinal, and pulmonary symptoms – particularly in immuno-
compromised patients who have been in endemic tropical 
and subtropical regions of the world. Although immuno-
competent patients with strongyloides infection often remain 
asymptomatic, the immunocompromised may present with 
disseminated and hyperinfection syndromes. Strongyloidiasis 
is diagnosed by the detection of larvae in stool or other bodily 
fluids. The first line treatment is a short course of oral ivermectin 
for patients with uncomplicated disease or a prolonged course 
for those with disseminated or hyperinfection syndromes.
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